Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

… Furthermore, as we proxy education or general intellectual achievement by schooling in
our empirical research, this has led to biased interpretations of impacts when general …

… We evaluated the effect of dexmedetomidine on neurologic and histopathologic outcome
from incomplete cerebral ischemia in the rat. Anesthesia was maintained with a 25-micrograms.…

… We have recently proposed the hypothesis that inhibition of the cyclic nucleotide … In the
present report, we describe the discovery of a new class of PDE10A inhibitors exemplified by TP-…

… We used a fentanyl infusion that has previously been shown to be effective in this … In
conclusion, we observed that dexmedetomidine treatment during open gastric bypass surgery …

Remifentanil is an esterase-metabolized opioid developed for use in anesthesia. The
principal metabolite of remifentanil, GR90291, is considered to be less potent. This study …

… To arrive at the top five similar articles we use a word-weighted algorithm to compare
words from the Title and Abstract of each citation. … Let us know how we are doing.How are …

… We hypothesized that patients with clinical evidence of ischemia would have changes in brain
… Therefore, we evaluated baseline levels of these variables, in patients with and without a …

… Discussion In this study we found that a non-opioid drug combination (ketorolac, clonidine,
lidocaine, ketamine, magnesium sulfate and methylprednisolone) produced adequate …

… We will resume services after this date. … We tested whether ketamine, an NMDA
antagonist, and NBQX, a non-NMDA antagonist, improve outcome from incomplete cerebral …